The only thing special about it, as I recall, was the FDA assigning more people than usual to the review so that the same workload of reviewing their trials and data could be done in less time.
they also had more staff working on it because they had no financial risk so they were able to use significantly more staff to do the work.
No steps were skipped nor were any corners cut.